Meritage Portfolio Management lifted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 102.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,559 shares of the company's stock after purchasing an additional 30,658 shares during the period. Meritage Portfolio Management's holdings in Cellebrite DI were worth $1,177,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the business. Gen Wealth Partners Inc acquired a new position in Cellebrite DI in the fourth quarter valued at approximately $85,000. NewEdge Advisors LLC increased its stake in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares in the last quarter. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $222,000. Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $234,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Cellebrite DI during the first quarter worth $269,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Analysts Set New Price Targets
Several research firms have weighed in on CLBT. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a research note on Friday, June 6th. JPMorgan Chase & Co. reduced their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of "Buy" and a consensus price target of $22.43.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Trading Up 0.8%
CLBT opened at $15.32 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.47 and a 1-year high of $26.30. The company has a market cap of $3.67 billion, a price-to-earnings ratio of -15.95, a PEG ratio of 3.07 and a beta of 1.28. The company's fifty day moving average price is $17.29 and its two-hundred day moving average price is $19.52.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The company had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. During the same period in the previous year, the firm posted $0.08 earnings per share. The firm's revenue for the quarter was up 20.0% on a year-over-year basis. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
